Skip to main content
. 2014 Sep 9;8(9-10):E583–E590. doi: 10.5489/cuaj.1891

Fig 2.

Fig 2.

Overall survival stratified by pre-abiraterone prostate-specific antigen doubling time (PSAdt). PSAdt >3 months (long dt) median survival 11 months (95% confidence interval [CI] 8.2, 13); PSAdt <3 months (short dt) median survival 7.8 months (95% CI 6.1, 13); negative PSAdt (negdt) median survival 18 months (95% CI 9.6, upper limit not reached).